ADVFN ADVFN

Hot Features

Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Pentixapharm Holding AG

Pentixapharm Holding AG (PTP)

2.42
-0.24
(-9.02%)
終了 6月5日 5:00AM

Pentixapharm Holding AG (PTP) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

主要統計と詳細

通貨
2.42
( -9.02% )
買値
2.32
売値
2.51
出来高
53,784
2.31 日の範囲 2.79
1.332 52 週間の範囲 3.90
時価総額
前日終値
2.66
始値
2.57
最終取引時間
財務取引量
-
VWAP
-
平均取引量 (3 か月)
7,738 €
発行済株式数
24,783,048
配当利回り
PER
-4.46
1 株当たり利益 (EPS)
-0.64
歳入
397k
純利益
-15.68M

Pentixapharm Holding AG について

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseas... Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company’s PentixaFor is being developed as a diagnostic tool for primary hypertension, a cause of hypertension, which is in Phase III trial. Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany. 詳細を表示

セクター
-
業界
-
ウェブサイト
本社
Berlin, Germany
設立
2026
Pentixapharm Holding AG is listed in the sector of the Tradegate (DE) with ticker PTP. The last closing price for Pentixapharm was 2.66 €. Over the last year, Pentixapharm shares have traded in a share price range of 1.332 € to 3.90 €.

Pentixapharm currently has 24,783,048 shares in issue. The market capitalisation of Pentixapharm is 59.97 € million. Pentixapharm has a price to earnings ratio (PE ratio) of -4.46.

PTP 最新ニュース

表示するニュースはありません。
期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.114.76190476192.312.952.31472172.70091877DE
40.390000119.21182853262.02999992.952.02270042.40466203DE
120.50826.56903765691.9122.951.744185932.19766948DE
260.92261.54873164221.4983.91.432727912.35284872DE
52-0.125-4.91159135562.5453.91.332454332.22611726DE
156-2.6799999-52.54901867745.09999997.3531.332412752.65947174DE
260-2.6799999-52.54901867745.09999997.3531.332412752.65947174DE

PTP - Frequently Asked Questions (FAQ)

What is the current Pentixapharm Holding AG share price?
The current share price of Pentixapharm Holding AG is 2.42 €
How many Pentixapharm Holding AG shares are in issue?
Pentixapharm Holding AG has 24,783,048 shares in issue
What is the market cap of Pentixapharm Holding AG?
The market capitalisation of Pentixapharm Holding AG is EUR 59.97M
What is the 1 year trading range for Pentixapharm Holding AG share price?
Pentixapharm Holding AG has traded in the range of 1.332 € to 3.90 € during the past year
What is the PE ratio of Pentixapharm Holding AG?
The price to earnings ratio of Pentixapharm Holding AG is -4.46
What is the cash to sales ratio of Pentixapharm Holding AG?
The cash to sales ratio of Pentixapharm Holding AG is 177.29
What is the registered address of Pentixapharm Holding AG?
The registered address for Pentixapharm Holding AG is Robert-Rössle-Straße 10, Berlin, Berlin, 13125
What is the Pentixapharm Holding AG website address?
The website address for Pentixapharm Holding AG is www.pentixapharm.com

PTP 取引

さらに

取引は遅延しています

リアルタイムの取引を取得するには、アカウントをアップグレードしてください

リアルタイムにアップグレード

最近閲覧した銘柄

Delayed Upgrade Clock